Metabolic Dysfunction-Associated Fatty Liver Disease on Distinct Microbial Communities at the Bacterial Phylum LevelOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers evaluated whether metabolic dysfunction-associated fatty liver disease (MAFLD) shifts fecal bacterial phylum composition. They compared 22 MAFLD patients against 21 non-MAFLD patients, all recruited from 43 people with chronic nonviral liver disease.
How was it studied?
Fecal samples were analyzed by 16S rRNA gene sequencing (V3-V4 region) via PCR and the MiSeq platform. Investigators compared relative phylum abundances and alpha diversity (Chao-1, Shannon indices) between groups, then correlated Firmicutes abundance with diversity in each group.
What did they find?
Sequences spanned ten phyla; Firmicutes relative abundance was significantly higher in MAFLD patients than non-MAFLD patients (51.4% vs 28.1%, p = 0.014), while Bacteroidetes was lower (35.4% vs 51.3%, p = 0.044). Overall microbial diversity did not differ significantly by MAFLD status (Chao-1 p = 0.215, Shannon p = 0.174), but the correlation between Firmicutes abundance and diversity was weaker in MAFLD patients than in non-MAFLD patients.
Why it matters
The findings suggest MAFLD is linked to a distinct Firmicutes-dominant phylum-level shift that decouples from the usual relationship between Firmicutes abundance and microbial diversity. The authors note obesity, more common in the MAFLD group, likely drives this Firmicutes increase.